Latham & Watkins advised Icosavax on the offering. Icosavax, Inc. (Nasdaq: ICVX) has announced that it has entered into a securities purchase agreement with investors in a...
Icosavax’s $67.8 Million Registered Direct Offering of Common Stock
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Icosavax’s $100 Million Series B Financing
Latham & Watkins LLP represented Icosavax, Inc. in the transaction. Icosavax, Inc. closed a US$100 million Series B Financing, led by RA Capital Management and joined by...